Differential antithrombotic therapy in patients with low and high PTCA risk
Review published in Herz (1996)
Abstract
UNLABELLED: Acute coronary occlusion as well as restenosis still represent the major limitations of coronary interventions. Either event seems to be related to thrombus formation. The purpose of this overview is to summarize the current status of the usefulness of conventional and newer antithrombotic drugs regarding the prevention of acute occlusion and restenosis (excluding stents). ANTICOAGULATION: For ethical reasons, no placebo-controlled studies were conducted to prove the usefulness of heparin in preventing acute occlusions. The dosage mostly used is 10,000 U, although a relationship between dosage and complication rate has not been documented. A prolonged heparin infusion in patients with low risk and uncomplicated PTCA has no advantages. Restenosis is not influenced by prolonged infusion of heparin or administration of coumadin as well. Low molecular weight heparin is currently under investigation. Hirudin and hirulog have shown promising results with less acute occlusions; however, their therapeutic range must be considered. ANTIAGGREGATION: In controlled studies, ASA significantly reduced acute occlusions during PTCA when given in addition to heparin. Ticlopidin is as effective as ASA, but due to its side effects should only be administered when contraindications to ASA exist. ASA significantly reduced restenosis in only 1 of 4 studies with limited number of patients. Thromboxane inhibitors such as ridogrel or clopidogrel showed promising initial results. Trapidil significantly reduced restenosis in 2 studies; quantitative stenosis analysis, however, was not performed. Inhibition of platelets by glycoprotein (GP) IIb/IIIa receptor antagonists represents an innovative therapeutic concept: numerous controlled trials have documented a significant reduction in cardiac ischemic events and therefore indirectly in restenosis rates. The recombinant monoclonal antibody c7E3 Fab seems to be more effective than the synthetic integrelin. Unfortunately, efficacy appears to be in direct relationship to the risk of bleeding complications. The clinical role of oral GP IIb/IIIa inhibitors has yet to be established. For patients with high risk PTCA, the use of hirudin instead of heparin as well as the addition of GP IIb/IIIa inhibitors should be considered.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Zusammenfassung
Acute coronary occlusion as well as restenosis still represent the major limitations of coronary interventions.
Warum dies für die Hirudotherapie relevant ist
Diese Übersichtsarbeit fasst den Status konventioneller und neuerer antithrombotischer Arzneimittel zur Prävention akuter Okklusion und Restenose nach koronarer Angioplastie (unter Ausschluss von Stents) zusammen, stratifiziert nach Patientenrisiko. Hirudin und Hirulog werden als "vielversprechende Ergebnisse mit weniger akuten Okklusionen" beschrieben, wobei das Abstract allerdings darauf hinweist, dass "ihr therapeutischer Bereich berücksichtigt werden muss." Die Übersichtsarbeit schlägt speziell vor, dass für Hochrisiko-PTCA-Patienten "die Verwendung von Hirudin anstelle von Heparin sowie die zusätzliche Gabe von GP-IIb/IIIa-Inhibitoren in Betracht gezogen werden sollten." Dies ist von indirekter Relevanz für den Bereich der ASH, da es Hirudin – ursprünglich aus medizinischen Blutegeln gewonnen – als klinisch relevante antithrombotische Alternative zu Heparin in der interventionellen Kardiologie behandelt. Die wesentliche Einschränkung besteht darin, dass es sich um eine Übersichtsarbeit ohne Originaldaten handelt; Hirudin wird nur kurz neben mehreren Wirkstoffen diskutiert, und es werden keine spezifischen Studienergebnisse oder Studiendesigns im Abstract angegeben.
Zitation
Verwandter klinischer Kontext
Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist
Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: 18. Juni 2026